Previous 10 |
BOSTON and ROCKVILLE, Md., March 22, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that it will be added to the Russell 2000...
BOSTON and ROCKVILLE, Md., March 09, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that John Celebi, President and Chief Executive Officer of ...
Gainers: [[SNSE]] +17.5%. [[ABCL]] +8.3%. [[AGLE]] +7.6%. [[OLED]] +5.9%. [[EOLS]] +5.4%.Losers: [[CRWD]] -7.0%. [[ARDX]] -6.9%. [[NK]] -6.6%. [[CATB]] -3.2%. [[ISEE]] -3.1%. For further details see: SNSE, AGLE, CRWD and ISEE among after-hours movers
Citi analyst Mohit Bansal has initiated shares of Sensei Biotherapeutics (SNSE) with a buy rating and $30 price target.Bansal bases his bullishness on the company's platform that is based on developing cancer vaccines based on bateriophages, which are viruses that infect bacteria.Known as Imm...
Insider buying decreased significantly last week. Notable Insider Buys: American Assets Trust, Inc., OPKO Health, Inc., Sonos, Inc., Franklin Street Properties Corp., Sensei Biotherapeutics, Inc. Notable Insider Sells: Walmart Inc., Hess Corporation, Facebook, Inc., Southern Coppe...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead Investors have a variety of events and developments to focus on next week. The impact of the pending FDA approval on Joh...
Two IPOs are scheduled to raise $1.3 billion in the week ahead. Street research is expected for 14 companies. Lock-up periods will be expiring for six companies. For further details see: U.S. IPO Week Ahead: Health Insurer Oscar Health Leads A 2 IPO Week
BOSTON and ROCKVILLE, Md., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced the closing of its initial public offering of 7,000,052 shar...
Cambrian Biopharma announces $60M in financing to develop a pipeline of companies and therapeutics to treat diseases of aging, coupled with a unique operational strategy Sensei Biotherapeutics, a Cambrian affiliate developing cancer vaccines, raised approximately $133 million th...
News, Short Squeeze, Breakout and More Instantly...
Sensei Biotherapeutics Inc. Company Name:
SNSE Stock Symbol:
NASDAQ Market:
Sensei Biotherapeutics Inc. Website:
A look at the top 10 most actives in the United States Innovative Eyewear Inc. (LUCY) rose 428.5% to $0.983 on volume of 924,758,481 shares Greenwave Technology Solutions Inc. (GWAV) fell 4.2% to $0.0849 on volume of 393,457,542 shares Netcapital Inc. (NCPL) rose 10.1% to $0.1925 on volum...
A look at the top 10 most actives in the United States Greenwave Technology Solutions Inc. (GWAV) fell 5.3% to $0.0839 on volume of 148,968,464 shares Netcapital Inc. (NCPL) rose 66.0% to $0.2901 on volume of 111,713,040 shares Cue Health Inc. (HLTH) rose 33.6% to $0.126 on volume of 99,7...
- Once every 3-week dosing of SNS-101 demonstrates initial signs of promising clinical activity - - Pharmacokinetic and safety profile validate conditionally active approach - - Investor webcast to be held on Monday, June 3 at 8:00 a.m. ET - BOSTON, May 23, 2024 (GLOBE NEW...